15.08.2024 14:22:38

Hoth, Aronnax Enter Master Services Agreement For HT-KIT Therapeutic - Quick Facts

(RTTNews) - Hoth Therapeutics (HOTH) has entered into a Master Services Agreement with Aronnax for its HT-KIT cancer therapeutic. HT-KIT is an antisense oligonucleotide that targets the proto-oncogene cKIT being developed for the treatment of mast cell-derived cancers and anaphylaxis and previously received Orphan Drug Designation from FDA.

"This further analysis will help us with that process, finalizing the protocols in our upcoming IND-enabling study. We are pleased to further engage Aronnax and ITR Laboratories on these key studies given their reputation for IND-enabling studies," stated Robb Knie, CEO.

For More Such Health News, visit rttnews.com.

Nachrichten zu Hoth Therapeutics Inc Registered Shsmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu Hoth Therapeutics Inc Registered Shsmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!